Volkan I Sayin1, Omar M Khan1, Lara E Pehlivanoglu1, Anna Staffas1, Mohamed X Ibrahim1, Annika Asplund1, Pia Agren1, Anna Nilton1, Göran Bergström1, Martin O Bergo1, Jan Borén1, Per Lindahl2. 1. From the Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine (V.I.S., L.E.P., A.A., P.Å., A.N., G.B., J.B., P.L.), Department of Biochemistry, Institute of Biomedicine (V.I.S., P.L.), and Department of Molecular and Clinical Medicine/Sahlgrenska Cancer Center, Institute of Medicine (O.M.K., A.S., M.X.I., M.O.B.), Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. 2. From the Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine (V.I.S., L.E.P., A.A., P.Å., A.N., G.B., J.B., P.L.), Department of Biochemistry, Institute of Biomedicine (V.I.S., P.L.), and Department of Molecular and Clinical Medicine/Sahlgrenska Cancer Center, Institute of Medicine (O.M.K., A.S., M.X.I., M.O.B.), Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. per.lindahl@wlab.gu.se.
Abstract
RATIONALE: Cell proliferation and cell cycle control mechanisms are thought to play central roles in the pathogenesis of atherosclerosis. The transcription factor Zinc finger protein 148 (Zfp148) was shown recently to maintain cell proliferation under oxidative conditions by suppressing p53, a checkpoint protein that arrests proliferation in response to various stressors. It is established that inactivation of p53 accelerates atherosclerosis, but whether increased p53 activation confers protection against the disease remains to be determined. OBJECTIVE: We aimed to test the hypothesis that Zfp148 deficiency reduces atherosclerosis by unleashing p53 activity. METHODS AND RESULTS: Mice harboring a gene-trap mutation in the Zfp148 locus (Zfp148(gt/+)) were bred onto the apolipoprotein E (Apoe)(-/-) genetic background and fed a high-fat or chow diet. Loss of 1 copy of Zfp148 markedly reduced atherosclerosis without affecting lipid metabolism. Bone marrow transplantation experiments revealed that the effector cell is of hematopoietic origin. Peritoneal macrophages and atherosclerotic lesions from Zfp148(gt/+)Apoe(-/-) mice showed increased levels of phosphorylated p53 compared with controls, and atherosclerotic lesions contained fewer proliferating macrophages. Zfp148(gt/+)Apoe(-/-) mice were further crossed with p53-null mice (Trp53(-/-) [the gene encoding p53]). There was no difference in atherosclerosis between Zfp148(gt/+)Apoe(-/-) mice and controls on a Trp53(+/-) genetic background, and there was no difference in levels of phosphorylated p53 or cell proliferation. CONCLUSIONS: Zfp148 deficiency increases p53 activity and protects against atherosclerosis by causing proliferation arrest of lesional macrophages, suggesting that drugs targeting macrophage proliferation may be useful in the treatment of atherosclerosis.
RATIONALE: Cell proliferation and cell cycle control mechanisms are thought to play central roles in the pathogenesis of atherosclerosis. The transcription factor Zinc finger protein 148 (Zfp148) was shown recently to maintain cell proliferation under oxidative conditions by suppressing p53, a checkpoint protein that arrests proliferation in response to various stressors. It is established that inactivation of p53 accelerates atherosclerosis, but whether increased p53 activation confers protection against the disease remains to be determined. OBJECTIVE: We aimed to test the hypothesis that Zfp148 deficiency reduces atherosclerosis by unleashing p53 activity. METHODS AND RESULTS:Mice harboring a gene-trap mutation in the Zfp148 locus (Zfp148(gt/+)) were bred onto the apolipoprotein E (Apoe)(-/-) genetic background and fed a high-fat or chow diet. Loss of 1 copy of Zfp148 markedly reduced atherosclerosis without affecting lipid metabolism. Bone marrow transplantation experiments revealed that the effector cell is of hematopoietic origin. Peritoneal macrophages and atherosclerotic lesions from Zfp148(gt/+)Apoe(-/-) mice showed increased levels of phosphorylated p53 compared with controls, and atherosclerotic lesions contained fewer proliferating macrophages. Zfp148(gt/+)Apoe(-/-) mice were further crossed with p53-null mice (Trp53(-/-) [the gene encoding p53]). There was no difference in atherosclerosis between Zfp148(gt/+)Apoe(-/-) mice and controls on a Trp53(+/-) genetic background, and there was no difference in levels of phosphorylated p53 or cell proliferation. CONCLUSIONS:Zfp148 deficiency increases p53 activity and protects against atherosclerosis by causing proliferation arrest of lesional macrophages, suggesting that drugs targeting macrophage proliferation may be useful in the treatment of atherosclerosis.
Authors: Morgan Salmon; Basil Schaheen; Michael Spinosa; William Montgomery; Nicolas H Pope; John P Davis; William F Johnston; Ashish K Sharma; Gary K Owens; Juanita L Merchant; Zendra E Zehner; Gilbert R Upchurch; Gorav Ailawadi Journal: Arterioscler Thromb Vasc Biol Date: 2019-01 Impact factor: 8.311
Authors: Christopher H Emfinger; Eleonora de Klerk; Kathryn L Schueler; Mary E Rabaglia; Donnie S Stapleton; Shane P Simonett; Kelly A Mitok; Ziyue Wang; Xinyue Liu; Joao A Paulo; Qing Yu; Rebecca L Cardone; Hannah R Foster; Sophie L Lewandowski; José C Perales; Christina M Kendziorski; Steven P Gygi; Richard G Kibbey; Mark P Keller; Matthias Hebrok; Matthew J Merrins; Alan D Attie Journal: JCI Insight Date: 2022-05-23
Authors: Bryan E Essien; Sinju Sundaresan; Ramon Ocadiz-Ruiz; Aaron Chavis; Amy C Tsao; Arthur J Tessier; Michael M Hayes; Amanda Photenhauer; Milena Saqui-Salces; Anthony J Kang; Yatrik M Shah; Balazs Győrffy; Juanita L Merchant Journal: Cancer Res Date: 2016-10-10 Impact factor: 12.701
Authors: Arghavan Ashouri; Volkan I Sayin; Jimmy Van den Eynden; Simranjit X Singh; Thales Papagiannakopoulos; Erik Larsson Journal: Nat Commun Date: 2016-10-25 Impact factor: 14.919